Genentech reveals facility expansion plans
Cell Culture Production 2 - or 'CCP2' - is the name US biotech giant Genentech has given to the rapidly planned expansion of its Vacaville facility, a project company officials hope will position the company as the world's leader in biotherapeutics by 2010.
Cell Culture Production 2 - or 'CCP2' - is the name US biotech giant Genentech has given to the rapidly planned expansion of its Vacaville facility, a project company officials hope will position the company as the world's leader in biotherapeutics by 2010.
Genentech official Mark Fischer unveiled details of Genentech's research and manufacturing operations, its goals and building plans.
'Horizons 2010' is Genentech's timeframe for reaching sustainable, long-term growth. This includes development and production of five new oncology products - to be placed on the market in 2010 - and getting five new immunology products into approved development and clinical trials the same year.
With the Vacaville manufacturing facility central to Genentech's growth, site clearing already is under way, with major excavation and construction scheduled to begin in September. The infrastructure will go up in early 2005, mechanical completion by February 2007, and licensing complete by June 2009.
Drugs manufactured at the Vacaville plant include Xolair, which treats acute asthma; Rituxan for non-Hodgkins lymphomas; and Herceptin for breast cancer. Fischer also unveiled the company's new logo: 'Genentech - In Business For Life.'